Standard BioTools Stock

Standard BioTools Stocks 2024

Standard BioTools Stocks

79.16 M

Ticker

LAB

ISIN

US34385P1084

WKN

A0RADJ

In 2024, Standard BioTools had 79.16 M outstanding stocks, a 0% change from the 79.16 M stocks in the previous year.

The Standard BioTools Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2027e79.16
2026e79.16
2025e79.16
2024e79.16
202379.16
202278.3
202175.8
202072
201966.8
201839.7
201733
201629
201527.8
201427.8
201325.5
201222.1
201117.8
20101.9
20091.7
20081.7
20071.6
20061.5
20051.5

Standard BioTools shares outstanding

The number of shares was Standard BioTools in 2023 — This indicates how many shares 79.16 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Standard BioTools earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Standard BioTools's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Standard BioTools’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Standard BioTools's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Standard BioTools Aktienanalyse

What does Standard BioTools do?

Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Standard BioTools's Shares Outstanding

Standard BioTools's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Standard BioTools’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Standard BioTools’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Standard BioTools’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Standard BioTools stock

How many stocks are there of Standard BioTools?

The current number of stocks of Standard BioTools is 79.16 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Standard BioTools are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Standard BioTools evolved in recent years?

The number of shares of Standard BioTools has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Standard BioTools as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Standard BioTools?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Standard BioTools pay?

Over the past 12 months, Standard BioTools paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Standard BioTools is expected to pay a dividend of 0 USD.

What is the dividend yield of Standard BioTools?

The current dividend yield of Standard BioTools is .

When does Standard BioTools pay dividends?

Standard BioTools pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Standard BioTools?

Standard BioTools paid dividends every year for the past 0 years.

What is the dividend of Standard BioTools?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Standard BioTools located?

Standard BioTools is assigned to the 'Health' sector.

Wann musste ich die Aktien von Standard BioTools kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Standard BioTools from 8/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2024.

When did Standard BioTools pay the last dividend?

The last dividend was paid out on 8/11/2024.

What was the dividend of Standard BioTools in the year 2023?

In the year 2023, Standard BioTools distributed 0 USD as dividends.

In which currency does Standard BioTools pay out the dividend?

The dividends of Standard BioTools are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Standard BioTools stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Standard BioTools

Our stock analysis for Standard BioTools Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Standard BioTools Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.